Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 7/20 | 0.38 |
| ▸ | SRC | P12931 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALPL | P05186 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606648 | 0.85 | MMP2 (0.52) | MMP2MAPK1XDHCYP1A2ABL1 | |
| SCHEMBL7424608 | 0.84 | MMP2 (0.61) | MMP2MAPK1XDHCYP1A2ABL1 | |
| SCHEMBL6105836 | 0.84 | MMP2 (0.43) | MMP2MAPK1GAAALDH1A1 | |
| SCHEMBL20630811 | 0.83 | MMP2 (0.60) | MMP2MAPK1XDHCYP1A2ABL1 | |
| SCHEMBL8653203 | 0.81 | MMP2 (0.67) | MMP2MAPK1XDHCYP1A2ABL1 | |
| SCHEMBL14744177 | 0.81 | MMP2 (0.67) | MMP2MAPK1XDHCYP1A2ABL1 | |
| SCHEMBL28296067 | 0.81 | MMP2 (0.58) | MMP2MAPK1XDHCYP1A2ABL1 | |
| SCHEMBL31373939 | 0.81 | MMP2 (0.58) | MMP2MAPK1XDHCYP1A2ABL1 | |
| Hydrochloric Acid SCHEMBL14744176 | 0.80 | MMP2 (0.65) | MMP2MAPK1XDHCYP1A2ABL1 | |
| SCHEMBL9605532 | 0.79 | MMP2 (0.56) | MMP2MAPK1XDHCYP1A2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569927-B1 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-7358268-B2 | Imidazole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| EP-1569927-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1479674-A1 | Imidiazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
| EP-1426364-A1 | Imidazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | TFPI, F11, TFPI2 | MMP2 220/4885MAPK1 1124/4885XDH 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.